Summary
Mazindol is a tricyclic anorexigenic agent approved for short-term obesity treatment and off-label narcolepsy management. Unlike amphetamines, it produces primarily dysphoric rather than euphoric effects, reducing abuse potential. Its dual mechanism targeting both monoamine reuptake and orexin-2 receptors makes it unique among stimulants. Common side effects include insomnia, dry mouth, anxiety, increased heart rate, and restlessness. Use with extreme caution in individuals with cardiovascular disease, hypertension, hyperthyroidism, or glaucoma.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Oral | 30-60 min | 30-90 min | 2-4 hrs | 4-8 hrs | 24 hrs |
Tolerance
Build-up
develops over days to weeks of regular use
Reset
3–7 days for acute tolerance; longer for full reset
Effects
Positive
- Increased alertness
- Physical Euphoria
- Muscle relaxation
- Physical euphoria
Negative
- Restlessness
- Insomnia
- Dry mouth
- Increased heart rate
- Motor impairment
- Sedation
Positive
- Wakefulness
- Focus enhancement
- Motivation enhancement
- Cognitive euphoria
Negative
- Anxiety
- Dysphoria
- Dizziness
- Drowsiness
- Motor control loss
- Confusion
Positive
Negative
- Appetite suppression
- Light sensitivity
- Disinhibition
- Acuity suppression
- Decreased Libido
- Acuity Suppression
- Visual acuity suppression
- Dulled perception
- Internal Hallucination
- Perception of bodily heaviness